Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 19:9:1016255.
doi: 10.3389/fcvm.2022.1016255. eCollection 2022.

One-stage hybrid coronary revascularization for the treatment of multivessel coronary artery disease- Periprocedural and long-term results from the "HYBRID-COR" feasibility study

Krzysztof Sanetra  1   2 , Piotr Paweł Buszman  3   4   5 , Justyna Jankowska-Sanetra  4 , Marek Cisowski  6 , Wojciech Fil  3   4 , Bogdan Gorycki  4 , Andrzej Bochenek  2   5   7 , Monika Slabon-Turska  8 , Marta Konopko  3 , Paweł Kaźmierczak  9 , Witold Gerber  2   7 , Krzysztof Milewski  4   5   7 , Paweł Eugeniusz Buszman  10
Affiliations

One-stage hybrid coronary revascularization for the treatment of multivessel coronary artery disease- Periprocedural and long-term results from the "HYBRID-COR" feasibility study

Krzysztof Sanetra et al. Front Cardiovasc Med. .

Abstract

Background: The constant growth of interest in hybrid coronary artery revascularization (HCR) is apparent. Yet, few studies report outcomes of the one-stage HCR. Consequently, the status of such procedures is not adequately supported in clinical guidelines. The aim of this study was to report the safety, feasibility, and long term-outcomes of the one-stage HCR.

Methods and results: Patients were enrolled in the prospective one-stage hybrid coronary revascularization program (HYBRID-COR). They underwent a one-stage hybrid revascularization procedure while on double antiplatelet therapy (DAPT) with Ticagrelor: endoscopic atraumatic coronary artery bypass grafting (EACAB) for revascularization of the left anterior descending (LAD) artery and percutaneous intervention in non-LAD arteries with contemporary drug-eluting stents. The composite primary endpoint included MACCE (major adverse cardiac and cerebrovascular events: death, myocardial infarction, stroke, and repeated revascularization) in long-term observation. The study cohort consisted of 30 patients (68% male) with stable coronary artery disease (26.7%) and unstable angina (73.3%). Procedural success was 100%. No death, myocardial infarction (MI), or stroke were observed in the perioperative period. One patient (3.3%) required chest revision and blood transfusion due to surgical bleeding. Kidney injury was noted in two patients (6.6%). In a long-term follow-up (median; IQR: 4.25; 2.62-4.69 years), two patients (6.6%) underwent repeated revascularization and one patient (3.3%) died due to MI. The overall primary endpoint rate was 9.9%.

Conclusion: One-stage hybrid revascularization, on DAPT, is a feasible, safe, and efficient way of achieving complete revascularization in selected patients. The complication rate is low and acceptable. Further randomized trials are required.

Keywords: EACAB; coronary artery disease; hybrid; one-stage; revascularization.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Kaplan–Meier curve for adverse events. MACCE, major adverse cardiac and cerebrovascular incidents (death, myocardial infarction, stroke, repeat revascularization); MI, myocardial infarction.
See this image and copyright information in PMC

References

    1. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. (2019) 40:87–165. 10.1093/eurheartj/ehy394 - DOI - PubMed
    1. De Bruyne B, Fearon WF, Pijls NH, Barbato E, Tonino P, Piroth Z, et al. Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med. (2014) 371:1208–17. 10.1056/NEJMoa1408758 - DOI - PubMed
    1. Windecker S, Stortecky S, Stefanini GG, da Costa BR, Rutjes AW, Di Nisio M, et al. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ. (2014) 23:g3859. 10.1136/bmj.g3859 - DOI - PMC - PubMed
    1. Gasior M, Zembala MO, Tajstra M, Filipiak K, Gierlotka M, Hrapkowicz T, et al. Hybrid revascularization for multivessel coronary artery disease. JACCCardiovasc Interv. (2014) 7:1277–83. 10.1016/j.jcin.2014.05.025 - DOI - PubMed
    1. Tajstra M, Hrapkowicz T, Hawranek M, Filipiak K, Gierlotka M, Zembala M, et al. Hybrid coronary revascularizationin selected patients with multivessel disease: 5-year clinical outcomes of the prospective randomized pilot study. JACC Cardiovasc Interv. (2018) 11:847–52. 10.1016/j.jcin.2018.01.271 - DOI - PubMed

LinkOut - more resources